BackRocket Pharmaceuticals- Warrants (02/09/2026) Overview

Rocket Pharmaceuticals- Warrants (02/09/2026) Current Cash

Latest current cash for RCKTW: $220M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$224.51M
584.08% YoYΔ $191.69M vs prior year quarter

Peer trimmed avg / median

Loading

Rocket Pharmaceuticals- Warrants (02/09/2026) Current Cash History

Loading

Rocket Pharmaceuticals- Warrants (02/09/2026) vs. peers: Current Cash Comparison

Loading

Rocket Pharmaceuticals- Warrants (02/09/2026) Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Rocket Pharmaceuticals- Warrants (02/09/2026) (RCKTW) FAQ

As of the most recent data (June 2026), RCKTW shows a current cash of $220M. That compares with $33M in the prior-year period — up 584.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RCKTW's current cash is now $220M (was $33M) — a 584.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Rocket Pharmaceuticals- Warrants (02/09/2026) is outperforming or lagging.

Tracking RCKTW's current cash over time shows whether Rocket Pharmaceuticals- Warrants (02/09/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $220M That compares with $33M in the prior-year period — up 584.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Rocket Pharmaceuticals- Warrants (02/09/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $220M) with ownership activity and broader fundamentals.

Rocket Pharmaceuticals- Warrants (02/09/2026)'s current cash is $220M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.